Disease · MONDO_0005365

hearing loss disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. hearing loss disorder. Diseases, record MONDO_0005365. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005365

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: hearing loss disorder; Open Targets
Open Targets ID: MONDO_0005365; Open Targets
Other names: hearing impairment, hearing loss, hypoacuses, hypoacusis, loss of hearing, loss, hearing; Open Targets
MeSH: D034381; MeSH
NCI Thesaurus: C35731; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 2 of its 13 drugs, from ClinicalTrials.gov; Open Targets

Drugs13

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DEXAMETHASONE	CHEMBL384467	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
VALGANCICLOVIR	CHEMBL1201314	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ZONISAMIDE	CHEMBL750	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
EBSELEN	CHEMBL51085	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
HYDROCORTISONE	CHEMBL389621	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PAROXETINE	CHEMBL490	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
VESTIPITANT	CHEMBL522987	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DANTROLENE SODIUM	CHEMBL928	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 13

See all 13 drugs

Targets17

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	3	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
ACHE	Acetylcholinesterase	1	Acetylcholinesterase inhibitor	Early phase 1	https://conductscience.org/library/genes/43	Drugs and targets
RYR1	Ryanodine receptor 1	1	Ryanodine receptor 1 antagonist	Phase 1/2	https://conductscience.org/library/genes/6261	Drugs and targets
RYR3	Ryanodine receptor 3	1	Ryanodine receptor 3 antagonist	Phase 1/2	https://conductscience.org/library/genes/6263	Drugs and targets
SCN10A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6323	Drugs and targets
SCN2A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6326	Drugs and targets
SCN3A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6328	Drugs and targets
SCN4A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6329	Drugs and targets

1 to 10 of 17

See all 17 targets

Trials13

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00466817	Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections	Phase 3	109	2013-11-13	Cytomegalovirus Infection	VALGANCICLOVIR	Its record names the disease	ClinicalTrials.gov
NCT04768569	Noise-Induced Hearing Loss-Acute Exposure Treatment	Phase 2	24	2025-01-15	Hearing Loss, Noise-Induced	ZONISAMIDE	Its record names the disease	ClinicalTrials.gov
NCT02829268	A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome	Phase 1/2	21	2024-03-13	Wolfram Syndrome, Diabetes Mellitus, Optic Nerve Atrophy, Ataxia	DANTROLENE SODIUM	Its record names the disease	ClinicalTrials.gov
NCT01207687	Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)	Phase 2	14	2017-08-17	Vestibular Schwannoma, Neurofibromatosis Type 2	BEVACIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT04774250	Noise-Induced Hearing Loss-Acute Exposure Treatment (UA)	Phase 2	3	2025-09-12	Hearing Loss, Noise-Induced	ZONISAMIDE	Its record names the disease	ClinicalTrials.gov
NCT00822263	The Use of Anti-oxidants to Reduce Sequela of Mild Traumatic Brain Injury (mTBI) After Blast Exposure	Not applicable	150		Mild Traumatic Brain Injury	ACETYLCYSTEINE	Its record names the disease	ClinicalTrials.gov
NCT05438264	Effect of Donepezil on Speech Recognition in Cochlear Implant Users	Early phase 1	50		Bilateral Sensorineural Hearing Loss	DONEPEZIL	Its record names the disease	ClinicalTrials.gov
NCT05112354	Predictive Factors for Recovery in Idiopathic Sensory Neural Hearing Loss	Phase 2	40		Idiopathic Sudden SNHL	HYDROCORTISONE, PREDNISOLONE	Its record names the disease	ClinicalTrials.gov
NCT06340633	SPI-1005 in Adults Receiving Cochlear Implant	Phase 2	40		Hearing Loss, Cochlear Trauma	EBSELEN	Its record names the disease	ClinicalTrials.gov
NCT04397354	Intracochlear Dexamethasone Application During Cochlear Implantation for Preserving Cochlear Cells	Not applicable	34		Hearing Loss, Sensorineural	DEXAMETHASONE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 13

See all 13 trials

Comparisons in its trials7

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Pediatric vs Adult: deaths from any cause	0 of 8	0 of 11	19	NCT02829268	Trial comparisons
Pediatric vs Adult: serious adverse events	0 of 8	0 of 11	19	NCT02829268	Trial comparisons
Treatment (Bevacizumab) - All Participants vs Treatment (Bevacizumab) - Pediatric Participants: Incidence of Serious or Life Threatening Toxicities	2 of 14	0 of 2	16	NCT01207687	Trial comparisons
Treatment (Bevacizumab) - All Participants vs Treatment (Bevacizumab) - Pediatric Participants: deaths from any cause	0 of 14	0 of 2	16	NCT01207687	Trial comparisons
Treatment (Bevacizumab) - All Participants vs Treatment (Bevacizumab) - Pediatric Participants: serious adverse events	2 of 14	0 of 2	16	NCT01207687	Trial comparisons
Zonisamide vs Placebo: deaths from any cause	0 of 1	0 of 2	3	NCT04774250	Trial comparisons
Zonisamide vs Placebo: serious adverse events	0 of 1	0 of 2	3	NCT04774250	Trial comparisons

Papers from its trials15

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
34185708	RESULT	1	PubMed
28207624	RESULT	1	PubMed
26976425	RESULT	1	PubMed
26972103	RESULT	1	PubMed
24232060	RESULT	1	PubMed
23818120	RESULT	1	PubMed
23044978	RESULT	1	PubMed
22383545	RESULT	1	PubMed
21221047	RESULT	1	PubMed
19923807	RESULT	1	PubMed

1 to 10 of 15

See all 15 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005365

GET https://conductscience.org/api/diseases/v1/MONDO_0005365/drugs

API reference For AI assistants